Cellectis S.A. (LON: 0WA2)

Market Cap	127.13M
Revenue (ttm)	26.89M
Net Income (ttm)	-63.03M
Shares Out	n/a
EPS (ttm)	-0.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	451
Open	n/a
Previous Close	1.516
Day's Range	n/a
52-Week Range	1.199 - 2.453
Beta	3.20
RSI	39.65
Earnings Date	Mar 5, 2025

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UC...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 221
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0WA2

Financial Performance

In 2023, Cellectis's revenue was $9.19 million, a decrease of -64.26% compared to the previous year's $25.72 million. Losses were -$101.06 million, -4.79% less than in 2022.

Financial numbers in USD